WO2004076682A3 - Cibles destinees a reguler la croissance cellulaire et destinees a des methodes de diagnostic - Google Patents

Cibles destinees a reguler la croissance cellulaire et destinees a des methodes de diagnostic Download PDF

Info

Publication number
WO2004076682A3
WO2004076682A3 PCT/US2004/006020 US2004006020W WO2004076682A3 WO 2004076682 A3 WO2004076682 A3 WO 2004076682A3 US 2004006020 W US2004006020 W US 2004006020W WO 2004076682 A3 WO2004076682 A3 WO 2004076682A3
Authority
WO
WIPO (PCT)
Prior art keywords
targets
diagnostic methods
cellular growth
controlling cellular
biomarker
Prior art date
Application number
PCT/US2004/006020
Other languages
English (en)
Other versions
WO2004076682A2 (fr
Inventor
Sergey A Axenovich
Robert Stull
Marina Gelman
Kitty Chui
Dean Ng
Original Assignee
Surromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surromed Inc filed Critical Surromed Inc
Publication of WO2004076682A2 publication Critical patent/WO2004076682A2/fr
Publication of WO2004076682A3 publication Critical patent/WO2004076682A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode permettant d'identifier un composé qui induit l'apoptose. Cette méthode consiste à identifier des composés qui inhibent l'expression et/ou l'activité d'une cible. L'invention concerne également des méthodes permettant d'induire l'apoptose en inhibant une des cibles. L'invention concerne enfin des méthodes permettant de diagnostiquer une tumeur. Ces méthodes consistent à déterminer le taux d'au moins une des cibles utilisée comme biomarqueur dans un échantillon de patient, le taux du biomarqueur étant représentatif de la présence de cellules tumorales.
PCT/US2004/006020 2003-02-26 2004-02-26 Cibles destinees a reguler la croissance cellulaire et destinees a des methodes de diagnostic WO2004076682A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45088603P 2003-02-26 2003-02-26
US60/450,886 2003-02-26

Publications (2)

Publication Number Publication Date
WO2004076682A2 WO2004076682A2 (fr) 2004-09-10
WO2004076682A3 true WO2004076682A3 (fr) 2006-09-28

Family

ID=32927686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006020 WO2004076682A2 (fr) 2003-02-26 2004-02-26 Cibles destinees a reguler la croissance cellulaire et destinees a des methodes de diagnostic

Country Status (1)

Country Link
WO (1) WO2004076682A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2525029A1 (fr) 2003-05-02 2004-11-18 Health Research, Inc. Utilisation de l'expression de jag2 dans le diagnostic de troubles de cellules plasmiques
CA2546017A1 (fr) 2003-11-26 2005-06-16 Health Research, Inc. Utilisation d'agents qui interferent avec la voie de transmission du signal notch pour le traitement des troubles plasmocytaires
GB2435882A (en) * 2006-03-09 2007-09-12 Bioinvent Int Ab Detection and treatment of mantle cell lymphoma
ES2570731T3 (es) * 2008-08-05 2016-05-20 Toray Industries Método de detección de cáncer
RU2498819C2 (ru) 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественных опухолей
MX2011005481A (es) 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
MX340014B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
US8828398B2 (en) 2010-02-04 2014-09-09 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
DK2532367T3 (en) 2010-02-04 2018-11-19 Toray Industries PHARMACEUTICAL AGENT FOR TREATMENT AND / OR CANCER PREVENTION
PT2741085T (pt) 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
PL2740798T3 (pl) 2011-08-04 2017-07-31 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworom
KR101980557B1 (ko) 2011-08-04 2019-05-21 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
AU2012290955B2 (en) 2011-08-04 2017-04-27 Toray Industries, Inc. Drug composition for cancer treatment and/or prevention
HUE047006T2 (hu) 2011-08-04 2020-04-28 Toray Industries Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
JP6065591B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112014021101A2 (pt) 2012-02-21 2022-03-22 Toray Industries Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo
DK2818481T3 (da) 2012-02-21 2019-10-14 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
AU2013223161B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
RU2640245C2 (ru) 2012-03-30 2017-12-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака печени
AU2013241043B2 (en) 2012-03-30 2017-11-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gall bladder cancer
BR112015001100A2 (pt) 2012-07-19 2018-03-27 Toray Industries, Inc. método de detecção de câncer
KR102056654B1 (ko) 2012-07-19 2019-12-17 도레이 카부시키가이샤 암의 검출 방법
WO2015020212A1 (fr) 2013-08-09 2015-02-12 東レ株式会社 Composition pharmaceutique pour le traitement et/ou la prévention du cancer
JP2018526443A (ja) * 2015-08-31 2018-09-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法
CN107012207B (zh) * 2017-03-03 2021-01-22 北京化工大学 Lrp5作为临床诊断和抑制消化系统肿瘤的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002055A2 (fr) * 2000-06-29 2002-01-10 Anadys Pharmaceuticals, Inc. Composes antifongiques et methodes d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002055A2 (fr) * 2000-06-29 2002-01-10 Anadys Pharmaceuticals, Inc. Composes antifongiques et methodes d'utilisation

Also Published As

Publication number Publication date
WO2004076682A2 (fr) 2004-09-10

Similar Documents

Publication Publication Date Title
WO2004076682A3 (fr) Cibles destinees a reguler la croissance cellulaire et destinees a des methodes de diagnostic
WO2005084109A3 (fr) Gène mh15 spécifique de cancer
WO2004111273A3 (fr) Marqueurs d'expression genique utilises en vue d'une reaction a des medicaments inhibiteurs de egfr
WO2010048123A3 (fr) Marqueurs biologiques prédictifs d'une réponse anticancéreuse à des inhibiteurs de récepteur kinase de facteur de croissance 1 de type insuline
WO2012024255A3 (fr) Camkk-bêta en tant que cible pour traiter le cancer
WO2006101925A3 (fr) Biomarqueurs predictifs de reponse anticancereuse a des inhibiteurs de kinase de recepteur de facteur de croissance epidermique
WO2011002850A8 (fr) Procédés pour déterminer la présence et/ou la concentration d'un analyte dans un échantillon
WO2006063042A3 (fr) Selection de patients pour une therapie avec un inhibiteur de her
WO2006085906A3 (fr) Methode de detection directe d'arn de diagnostic
WO2005115435A3 (fr) Methodes et compositions de lutte contre les maladies de la croissance foetale par modulation de la relaxine
WO2006096861A3 (fr) Methodes permettant d'identifier des tumeurs sensibles au traitement par des inhibiteurs de dimerisation her (hdi)
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
WO2004097052A3 (fr) Procedes de pronostic et de traitement de tumeurs solides
EP2177628A3 (fr) Marqueurs pour le diagnostic du cancer et leur utilisation
WO2006025028A3 (fr) Nouvelle methode de classification des globules sanguins servant de base a des activites therapeutiques et preventives sur mesure
WO2006130720A3 (fr) Purification, caracterisation et reconstitution d'une ubiquitine e3 ligase
WO2008084319A3 (fr) Nouvel acide nucléique
WO2008072777A3 (fr) Ttk utilisé en tant que marqueur tumoral et cible thérapeutique pour cancer du poumon
WO2005113797A3 (fr) PROCÉDÉS SERVANT À DÉTECTER L'ACTIVITÉ DE LA Lp-PLA2 ET L'INHIBITION DE L'ACTIVITÉ DE LA Lp-PLA2
WO2005118875A3 (fr) Diagnostic et prévision de l’évolution du cancer du sein
WO2007061922A3 (fr) Methodes de prediction et prevention de la resistance a des composes taxoides
WO2005040421A3 (fr) Marqueurs de pronostic et de diagnostic des troubles de proliferation cellulaire dans les tissus mammaires
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2007085497A3 (fr) Marqueurs de prévision des résultats d'un traitement à l'anthracycline
WO2005083086A3 (fr) L'EphA4 COMME CIBLE THÉRAPEUTIQUE DU PCR ET DU PDACa

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase